ID Week 2024: Key Updates in UTIs

Wendy Cheng, PhD, MPH, discusses how the largest unmet needs in the landscape of urinary tract infections (UTIs) include addressing antimicrobial resistance, improving treatment options for resistant strains, and developing novel therapies to fill gaps in current UTI management.

Wendy Cheng, PhD, MPH, discusses how the study on the efficacy of gepotidacin vs nitrofurantoin in a nitrofurantoin-resistant population (a pooled analysis of the EAGLE-2 and EAGLE-3 trials) aimed to evaluate the effectiveness of gepotidacin as a first-in-class oral therapy for uncomplicated urinary tract infections (uUTIs), showing promising results in overcoming antimicrobial resistance and potentially filling critical gaps in current UTI treatments.